CanSino Biologics Inc. (HKG:6185)
26.70
-0.46 (-1.69%)
Nov 11, 2026, 4:08 PM HKT
CanSino Biologics Employees
CanSino Biologics had 1,175 employees as of June 30, 2026. The number of employees increased by 41 or 3.62% since the number was reported on December 31, 2025. That makes CanSino Biologics the 13,724th largest employer in the world and 968th in Hong Kong.
Employees
1,175
Change
41
Growth
3.62%
Revenue / Employee
1.30M HKD
Profits / Employee
30.66K HKD
Market Cap
13.81B
Employees Chart
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 1,175 | 41 | 3.62% |
| Dec 31, 2025 | 1,134 | 29 | 2.62% |
| Dec 31, 2024 | 1,105 | -389 | -26.04% |
| Dec 31, 2023 | 1,494 | -797 | -34.79% |
| Dec 31, 2022 | 2,291 | 345 | 17.73% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| The United Laboratories International Holdings | 18,000 |
| Grand Pharmaceutical Group | 12,326 |
| Shandong Xinhua Pharmaceutical Company | 7,015 |
| China Medical System Holdings | 6,415 |
| Sunshine Lake Pharma | 6,299 |
| SSY Group | 5,400 |
| Consun Pharmaceutical Group | 2,847 |
| Sihuan Pharmaceutical Holdings Group | 2,712 |
CanSino Biologics News
- 3 months ago - Chinese drugmakers with big ambitions struggle to recruit staff for global expansion - Reuters
- 9 months ago - CanSinoBIO at WGS 2026: Accelerating Global Access to Innovative Vaccines - PRNewsWire
- 3 years ago - World-First Inhaled COVID-19 Vaccine, Developed in Partnership Between Aerogen® and CanSinoBIO, First Public Booster Immunization in China. - Business Wire
- 4 years ago - China's CanSinoBIO H1 revenue drops on weaker COVID shot demand - Reuters
- 4 years ago - CanSinoBIO's COVID-19 Vaccine Convidecia™ Receives WHO Emergency Use Listing - PRNewsWire
- 4 years ago - CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research - PRNewsWire
- 4 years ago - CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - PRNewsWire
- 4 years ago - CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia - PRNewsWire